GlassScriptPhysician profile
Catherine Rossi
NPI 1841274883
$1,006.82
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $107 · 2021: $513 · 2022: $152.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $342.79 | 2019-2022 | |
| Genentech USA, INC. | $137.99 | 2021 | |
| Sunovion Pharmaceuticals INC. | $120.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $70.89 | 2022 | |
| Astellas Pharma US INC | $63.01 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $44.27 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $39.72 | 2019-2021 | |
| Pfizer INC. | $32.29 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $31.06 | 2021 | |
| Novo Nordisk INC | $27.01 | 2019-2020 | |
| Lilly USA, LLC | $26.44 | 2020-2021 | |
| Esperion Therapeutics, INC. | $25.81 | 2021 | |
| Glaxosmithkline, LLC. | $25.29 | 2019 | |
| Sanofi Pasteur INC. | $19.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Rossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.